SUMO-1 prevents ERβ degradation by competing with ubiquitin at the same receptor site and inhibits ERβ transcription by changing estrogen-responsive target promoter occupancy and gene expression in breast cancer cells [106]. Here, ESR2 is linked to breast cancer.